Patents Assigned to KRIPTIC PHARMACEUTICALS LIMITED

Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert

Publication number: 20240325511

Abstract: The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing TERT.

Type: Application

Filed: June 14, 2024

Publication date: October 3, 2024

Applicant: KRIPTIC PHARMACEUTICALS LIMITED

Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet, Catherine Gallou, Aude Rougeot
Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing tert

Patent number: 12048737

Abstract: The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing TERT.

Type: Grant

Filed: May 4, 2018

Date of Patent: July 30, 2024

Assignee: KRIPTIC PHARMACEUTICALS LIMITED

Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet, Catherine Gallou, Aude Rougeot

Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert

Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing tert